PRINCETON, N.J., Jul 25, 2007 (BUSINESS WIRE) -- Derma Sciences (DSCI) , a manufacturer and marketer of advanced wound care products, today announced that the September 2007 issue of the journal WOUNDS: A Compendium of Clinical Research and Practice (WOUNDS) will feature an article on the use of a manuka honey-based product as a topical antimicrobial for chronic and acute wounds and burns. The article, "Medihoney(TM) Antibacterial Honey--in-vitro Activity Against Clinical Isolates of MRSA, VRE, and Other Multiresistant Gram-negative Organisms Including Pseudomonas aeruginosa" was written by Narelle May George, Supervising Scientist Queensland Health Pathology Service, Royal Brisbane Hospitals Campus, Herston, Queensland, Australia, and Keith F. Cutting, Tissue Viability Specialist, Harefield Hospital, Middlesex, Principal Lecturer - Tissue Viability, Buckinghamshire Chilterns University College, Chalfont St. Giles, UK.
The in-vitro study focuses on the antimicrobial effectiveness of a leading global brand of honey-based wound dressing, Medihoney(TM) (Medihoney Pty Ltd, Richlands, Australia). The product contains a blend of honeys, including Leptospermum honeys Manuka (from New Zealand) and its sister species Jelly Bush, from Australia. These Leptospermum honeys have been shown to provide strong, broad-spectrum antimicrobial activity even in the presence of catalase--an enzyme present in wound fluid. Medihoney is owned by Comvita, Derma Sciences' partner in honey-based dressings, and is available in Europe, Australia, and South East Asia.
The abstract for the WOUNDS article by George NM and Cutting KF to be published in September is as follows:
"The clinical use of honey has received increasing interest in recent years, in particular as a topical antibacterial dressing. Results so far are extremely encouraging, demonstrating that honey is effective against a broad range of microorganisms including multiresistant strains. The in-vitro study reported here complements the work of others and focuses on the impact that a standardized honey can have on multiresistant bacteria that are regularly found in wounds and are responsible for increased morbidity."
About WOUNDS: WOUNDS is the most widely read, peer-reviewed journal focusing on wound research and care. The information disseminated to their readers includes valuable research and commentaries on tissue repair and regeneration, biology, and biochemistry of wound healing, and clinical management of wounds of various etiologies. It is the only wound care journal dedicated to the physician market.
About Derma Sciences: Derma Sciences is a manufacturer and marketer of advanced wound care products, with operations based in the US and Canada, and sales worldwide. The company sources Active Manuka Honey from Comvita New Zealand, Ltd. Comvita controls over 70% of the flow of manuka honey, and owns several patents around the use of honey in wound dressings. In February 2006, Derma Sciences and Comvita entered into a licensing agreement granting Derma Sciences the exclusive rights to Comvita's technology and honey for marketing and sale to healthcare professionals into the North, South, and Central American markets. Derma Sciences is also the global manufacturer for the Comvita brand of several of the honey-based dressings. Comvita owns 14% of Derma Sciences stock (10% fully diluted), DSCI.OB. In June 2007, Derma Sciences' API-MED(TM) Antimicrobial Dressing with Active Manuka Honey was cleared by Health Canada. In July 2007, Derma Sciences' API-MED(TM) Active Manuka Honey Absorbent Dressing was cleared by the FDA. For more information about Derma Sciences, Inc., visit its home page on the Internet at http://www.dermasciences.com.
Statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned, that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements which may be made in this release or which are otherwise made by or on behalf of the Company. Factors which may affect the Company's results include, but are not limited to, product demand, market acceptance, impact of competitive products and prices, product development, completion of an acquisition, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements Include but are not limited to, those discussed in the Company's filings with the Securities and Exchange Commission.